Report cover image

Global Age Related Macular Degeneration Drug Competitive Landscape Professional Research Report 2024

Publisher DIResearch
Published Jun 10, 2024
Length 170 Pages
SKU # DIR18896921

Description

Global Age Related Macular Degeneration Drug Competitive Landscape Professional Research Report 2024



Research Summary

Age-related macular degeneration (AMD) drugs are medications used to treat the progressive and irreversible disease that affects the central part of the retina (macula) and can lead to vision loss. The main drugs used to treat AMD are anti-VEGF (vascular endothelial growth factor) medications. These drugs work by targeting and inhibiting the growth of abnormal blood vessels that can leak and cause damage to the macula. Some examples of anti-VEGF drugs used to treat AMD include Avastin, Lucentis, and Eylea. These drugs are usually administered via injection into the affected eye by a qualified healthcare professional. Other medications may also be prescribed to manage symptoms and prevent further vision loss.

According to DIResearch's in-depth investigation and research, the global Age Related Macular Degeneration Drug market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Age Related Macular Degeneration Drug include Regeneron Pharmaceuticals, Bayer HealthCare, Novartis, Roche, Kanghong Pharma etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Age Related Macular Degeneration Drug. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Age Related Macular Degeneration Drug market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Age Related Macular Degeneration Drug market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Age Related Macular Degeneration Drug industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Age Related Macular Degeneration Drug Include:

Regeneron Pharmaceuticals

Bayer HealthCare

Novartis

Roche

Kanghong Pharma

Age Related Macular Degeneration Drug Product Segment Include:

Lucentis

Eylea

Avastin

Others

Age Related Macular Degeneration Drug Product Application Include:

Hospitals

Clinics

Others

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Age Related Macular Degeneration Drug Industry PESTEL Analysis

Chapter 3: Global Age Related Macular Degeneration Drug Industry Porter’s Five Forces Analysis

Chapter 4: Global Age Related Macular Degeneration Drug Major Regional Market Size and Forecast Analysis

Chapter 5: Global Age Related Macular Degeneration Drug Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Age Related Macular Degeneration Drug Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Age Related Macular Degeneration Drug Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources

Table of Contents

170 Pages
1 Age Related Macular Degeneration Drug Market Overview
1.1 Product Definition and Statistical Scope
1.2 Age Related Macular Degeneration Drug Product by Type
1.2.1 Global Age Related Macular Degeneration Drug Market Size by Type, 2023 VS 2024 VS 2030
1.2.2 Lucentis
1.2.3 Eylea
1.2.4 Avastin
1.2.5 Others
1.3 Age Related Macular Degeneration Drug Product by Application
1.3.1 Global Age Related Macular Degeneration Drug Market Size by Application, 2023 VS 2024 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Age Related Macular Degeneration Drug Market Revenue Analysis (2019-2030)
1.5 Age Related Macular Degeneration Drug Market Development Status and Trends
1.5.1 Age Related Macular Degeneration Drug Industry Development Status Analysis
1.5.2 Age Related Macular Degeneration Drug Industry Development Trends Analysis
2 Age Related Macular Degeneration Drug Market PESTEL Analysis
2.1 Political Factors Analysis
2.2 Economic Factors Analysis
2.3 Social Factors Analysis
2.4 Technological Factors Analysis
2.5 Environmental Factors Analysis
2.6 Legal Factors Analysis
3 Age Related Macular Degeneration Drug Market Porter's Five Forces Analysis
3.1 Competitive Rivalry
3.2 Threat of New Entrants
3.3 Bargaining Power of Suppliers
3.4 Bargaining Power of Buyers
3.5 Threat of Substitutes
4 Global Age Related Macular Degeneration Drug Market Analysis by Regions
4.1 Age Related Macular Degeneration Drug Overall Market: 2023 VS 2024 VS 2030
4.2 Global Age Related Macular Degeneration Drug Revenue and Forecast Analysis (2019-2030)
4.2.1 Global Age Related Macular Degeneration Drug Revenue and Market Share by Region (2019-2024)
4.2.2 Global Age Related Macular Degeneration Drug Revenue Forecast by Region (2025-2030)
5 Global Age Related Macular Degeneration Drug Market Size by Type and Application
5.1 Global Age Related Macular Degeneration Drug Market Size by Type
5.2 Global Age Related Macular Degeneration Drug Market Size by Application
6 North America
6.1 North America Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
6.2 North America Key Manufacturers Analysis
6.3 North America Age Related Macular Degeneration Drug Market Size by Type
6.4 North America Age Related Macular Degeneration Drug Market Size by Application
6.5 North America Age Related Macular Degeneration Drug Market Size by Country
6.5.1 US
6.5.2 Canada
7 Europe
7.1 Europe Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
7.2 Europe Key Manufacturers Analysis
7.3 Europe Age Related Macular Degeneration Drug Market Size by Type
7.4 Europe Age Related Macular Degeneration Drug Market Size by Application
7.5 Europe Age Related Macular Degeneration Drug Market Size by Country
7.5.1 Germany
7.5.2 France
7.5.3 United Kingdom
7.5.4 Italy
7.5.5 Spain
7.5.6 Benelux
8 China
8.1 China Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
8.2 China Key Manufacturers Analysis
8.3 China Age Related Macular Degeneration Drug Market Size by Type
8.4 China Age Related Macular Degeneration Drug Market Size by Application
9 APAC (excl. China)
9.1 APAC (excl. China) Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
9.2 APAC (excl. China) Key Manufacturers Analysis
9.3 APAC (excl. China) Age Related Macular Degeneration Drug Market Size by Type
9.4 APAC (excl. China) Age Related Macular Degeneration Drug Market Size by Application
9.5 APAC (excl. China) Age Related Macular Degeneration Drug Market Size by Country
9.5.1 Japan
9.5.2 South Korea
9.5.3 India
9.5.4 Australia
9.5.5 Indonesia
9.5.6 Vietnam
9.5.7 Malaysia
9.5.8 Thailand
10 Latin America
10.1 Latin America Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
10.2 Latin America Key Manufacturers Analysis
10.3 Latin America Age Related Macular Degeneration Drug Market Size by Type
10.4 Latin America Age Related Macular Degeneration Drug Market Size by Application
10.5 Latin America Age Related Macular Degeneration Drug Market Size by Country
10.5.1 Mecixo
10.5.2 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Age Related Macular Degeneration Drug Market Size and Growth Rate Analysis (2019-2030)
11.2 Middle East & Africa Key Manufacturers Analysis
11.3 Middle East & Africa Age Related Macular Degeneration Drug Market Size by Type
11.4 Middle East & Africa Age Related Macular Degeneration Drug Market Size by Application
11.5 Middle East & Africa Age Related Macular Degeneration Drug Market Size by Country
11.5.1 Saudi Arabia
11.5.2 South Africa
12 Market Competition by Manufacturers
12.1 Global Age Related Macular Degeneration Drug Market Revenue by Key Manufacturers (2020-2024)
12.2 Age Related Macular Degeneration Drug Competitive Landscape Analysis and Market Dynamic
12.2.1 Age Related Macular Degeneration Drug Competitive Landscape Analysis
12.2.2 Global Key Manufacturers Headquarter and Key Area Sales
12.2.3 Market Dynamic
13 Key Companies Analysis
13.1 Regeneron Pharmaceuticals
13.1.1 Regeneron Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.1.2 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Product Portfolio
13.1.3 Regeneron Pharmaceuticals Age Related Macular Degeneration Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.2 Bayer HealthCare
13.2.1 Bayer HealthCare Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.2.2 Bayer HealthCare Age Related Macular Degeneration Drug Product Portfolio
13.2.3 Bayer HealthCare Age Related Macular Degeneration Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.3 Novartis
13.3.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.3.2 Novartis Age Related Macular Degeneration Drug Product Portfolio
13.3.3 Novartis Age Related Macular Degeneration Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.4 Roche
13.4.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.4.2 Roche Age Related Macular Degeneration Drug Product Portfolio
13.4.3 Roche Age Related Macular Degeneration Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.5 Kanghong Pharma
13.5.1 Kanghong Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.5.2 Kanghong Pharma Age Related Macular Degeneration Drug Product Portfolio
13.5.3 Kanghong Pharma Age Related Macular Degeneration Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
14 Industry Chain Analysis
14.1 Age Related Macular Degeneration Drug Industry Chain Analysis
14.2 Age Related Macular Degeneration Drug Industry Raw Material and Suppliers Analysis
14.2.1 Upstream Key Raw Material Supply Analysis
14.2.2 Raw Material Suppliers and Contact Information
14.3 Age Related Macular Degeneration Drug Typical Downstream Customers
14.4 Age Related Macular Degeneration Drug Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source
16.1 Methodology/Research Approach
16.2 Research Scope
16.3 Benchmarks and Assumptions
16.4 Date Source
16.4.1 Primary Sources
16.4.2 Secondary Sources
16.5 Data Cross Validation
16.6 Disclaimer

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us